Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada
复制标题
DOI：
10.1016/s2213-8587(22)00114-0
复制
发表时间：
2022-07-01
影响因子：
44.5
通讯作者：
Shapiro, A. M. James
中科院分区：
文献类型：
--
作者：
Marfil-Garza, Braulio A.;Imes, Sharleen;Shapiro, A. M. James
背景胰岛移植为1型糖尿病和顽固性低血糖患者提供了有效的治疗方法。然而，长期经验仍然有限。我们报告的结果，从一个单中心队列长达20年后胰岛transplantation.Methods这个队列研究包括18岁以上的1型糖尿病患者之间进行同种异体胰岛移植1999年3月11日，2019年10月1日，在大学的阿尔伯塔医院（埃德蒙顿，AB，加拿大）。纳入接受肾移植后胰岛移植和单独胰岛移植或全胰腺移植前胰岛移植的患者（随访在全胰腺移植时删失）。报告了患者存活率、移植物存活率（空腹血浆C肽>0.1 nmol/L）、胰岛素依赖性、血液病控制和不良事件。为了确定与移植物存活延长相关的因素，将移植物持续存活（>= 90%的患者随访时间）的受体与移植物非持续存活的受体进行比较（
Background Islet transplantation offers an effective treatment for selected people with type 1 diabetes and intractable hypoglycaemia. Long-term experience, however, remains limited. We report outcomes from a single-centre cohort up to 20 years after islet transplantation.Methods This cohort study included patients older than 18 years with type 1 diabetes undergoing allogeneic islet transplantation between March 11, 1999, and Oct 1, 2019, at the University of Alberta Hospital (Edmonton, AB, Canada). Patients who underwent islet-after-kidney transplantation and islet transplantation alone or islet transplantation before whole-pancreas transplantation ( follow-up was censored at the time of whole-pancreas transplantation) were included. Patient survival, graft survival ( fasting plasma C-peptide >0.1 nmol/L), insulin independence, glycaemic control, and adverse events are reported. To identify factors associated with prolonged graft survival, recipients with sustained graft survival (>= 90% of patient follow-up duration) were compared with those who had non-sustained graft survival (